参芪复方对糖尿病大血管病变大鼠胸主动脉差异基因表达的影响

发布时间：2019-02-17 19:56

【摘要】：目的探讨参芪复方防治糖尿病大血管病变的可能分子机制。方法 160只自发性2型糖尿病GK大鼠给予高脂饲料喂养12周建立糖尿病大血管病变模型,随机分成模型组、西药组、参高组、参中组、参低组,每组32只。另设32只Wistar大鼠为空白组。造模后西药组给予二甲双胍片0.1 g/(kg·d)灌胃,参高、中、低组分别给予参芪复方2.88、1.44、0.72 g/(kg·d)灌胃,空白组和模型组给予生理盐水5 ml/(kg·d)灌胃,各组均灌胃16周。分别在给药前及给药第8、16周时检测空腹血糖;第8、16周时采用Masson染色观察胸主动脉病理形态,计算胶原纤维/血管壁面积(PVCA/LA);16周时进行差异基因筛选。结果与空白组同时间比较,模型组在给药前及给药8、16周时大鼠空腹血糖升高,第8、16周时PVCA/LA明显升高(P0.05或P0.01);第16周时西药组和参高、中、低组大鼠空腹血糖低于同时间模型组,PVCA/LA均显著下降(P0.05或P0.01)。参中组与模型组、模型组与空白组共同存在的显著性差异基因共15个,其中与糖尿病血管病变有关的基因为Elavl1、Lama4,且参中组Elavl1、Lama4基因较模型组下调。结论参芪复方防治糖尿病大血管病变作用机理可能与下调胸主动脉Elavl1、Lama4基因表达,从而抑制血管新生,减少胶原纤维产生有关。
[Abstract]:Objective to explore the possible molecular mechanism of Shenqi compound in prevention and treatment of diabetic macrovascular disease. Methods one hundred and sixty GK rats with spontaneous type 2 diabetes mellitus were fed with high fat diet for 12 Zhou Jianli diabetic macroangiopathy models. They were randomly divided into three groups: model group, western medicine group, Shengao group, Shenzhong group and Shen-low group, with 32 rats in each group. Another 32 Wistar rats were set up as blank group. After model making, the western medicine group was given metformin tablet 0.1 g / (kg d) intragastric perfusion, Shengao, middle and low groups were given Shenqi compound 2.88 1.44 脳 0.72 g / (kg d) respectively. The blank group and the model group were given normal saline for 5 ml/ (kg d), and each group was given intragastric administration for 16 weeks. Fasting blood glucose was detected before administration and at 816 weeks after administration, Masson staining was used to observe the pathological morphology of thoracic aorta at 816 weeks, collagen fiber / vascular wall area (PVCA/LA) was calculated, and differential gene screening was carried out at 16 weeks. Results compared with the blank group, the fasting blood glucose in the model group increased before administration and at 816 weeks, and the PVCA/LA increased significantly at 816 weeks (P0.05 or P0.01). At the 16th week, the fasting blood glucose in the western medicine group and Shengao, middle and low groups was lower than that in the same time model group, and PVCA/LA decreased significantly (P0.05 or P0.01). There were 15 gene differences between model group and blank group, in which the gene related to diabetic vascular disease was Elavl1,Lama4, and Elavl1,Lama4 gene was down-regulated in reference group compared with model group. Conclusion the mechanism of Shenqi compound in prevention and treatment of diabetic macroangiopathy may be related to the down-regulation of Elavl1,Lama4 gene expression in thoracic aorta, thereby inhibiting angiogenesis and reducing the production of collagen fibers.
【作者单位】：成都中医药大学;
【基金】：国家自然科学基金(81273749) 四川省教育厅基金(14ZB0102)
【分类号】：R285.5

【相似文献】